Results 91 to 100 of about 13,813 (161)

Complete response following trastuzumab-deruxtecan in a man with HER2-overexpressing metastatic, poorly differentiated scrotal carcinoma. [PDF]

Oncologist
Hofstad M, Zheng J, Tachibana I, Zhang T.   +3 more
europepmc   +1 more source

Regulation of cell motility by ephrin-B2 signalling

, 2008
Ephrin ligands and their Eph receptor tyrosine kinases both are surface tethered proteins that control cell shape and movements through direct cell-cell contact.
Bochenek, Magdalena Ludmila
core  

A stage IV high-grade serous ovarian cancer patient carrying ERBB2 amplification and ERBB2 overexpression benefits from late-line pyrotinib treatment: A case report. [PDF]

Sci Prog
Zhu B, Liu Y, Li J, Yang W.
europepmc   +1 more source

CDK4/6 inhibitors rechallenge post-progression in HR-positive HER2-negative advanced/metastatic breast cancer patients: a meta-analysis of Kaplan-Meier-reconstructed individual-level data. [PDF]

Breast Cancer Res
Veta Darkovski J, Michelon I, Gazzoni G, Mamede I, Jeong Y, Cavalcante L.   +5 more
europepmc   +1 more source

Structural and functional investigation of the cytoplasmic domain of the Fas death receptor

, 2015
Activation of the transmembrane death receptor Fas (CD95/APO-1) by a membrane bound ligand (FasL/CD95L) activates the extrinsic pathway of apoptosis. Intracellular Fas death domains (DDs) are induced to oligomerise enabling binding to the adaptor protein
Wildsmith, GC
core  

Long Non-Coding RNAs in HER2-Positive Breast Cancer: From Resistance Mechanisms to Translational Potential. [PDF]

Oncol Res
Vo TH, McNeela E, O'Donnovan O, Prakash Mehta J, Nguyen VH, Rani S.   +5 more
europepmc   +1 more source

Molecular insights into HER2/ERBB2 amplification and carcinogenesis in gallbladder cancer associated with pancreaticobiliary maljunction. [PDF]

J Gastroenterol
Zhu M, Douchi D, Murakami K, Itoh T, Migita S, Rikiyama N, Hayashi S, Kokumai T, Sato H, Yoshimachi S, Kusaka A, Shimura M, Nakayama S, Aoki S, Iseki M, Miura T, Maeda S, Ishida M, Ohtsuka H, Mizuma M, Nakagawa K, Masamune A, Furukawa T, Unno M.   +23 more
europepmc   +1 more source

Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expression. [PDF]

Einstein (Sao Paulo)
Amarger CD, Rabello MIS, Skaf SC, Moura F, Cassoli JPB, Taranto P, Serrano Usón Junior PL, Kaliks R, Beal JR.   +8 more
europepmc   +1 more source

Clinical Implications of Erb-B2 Receptor Tyrosine Kinase 2 S310 Mutations in Non–Small-Cell Lung Cancer: Two Case Reports

Hong Kong Journal of Radiology
Q Du, TY Kam, MW Yeung
openaire   +1 more source

Decoding the landscape of bispecific antibodies in breast cancer: insights from a comprehensive trial analysis. [PDF]

Front Immunol
Yang S, Chuan Z, Yang S, Nie J.
europepmc   +1 more source